CLOs on the Move

The Upper Missouri District Health Unit

www.umdhu.org

 
The Upper Missouri District Health Unit is a Williston, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.umdhu.org
  • 110 W Broadway Ste 202
    Williston, ND USA 58801
  • Phone: 701.774.6400

Executives

Name Title Contact Details

Similar Companies

Intrinsic Therapeutics

Intrinsic Therapeutics, Inc is a MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BeneChill

BeneChill is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Primary Provider Management Company

Primary Provider Management Company is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hand And Stone

Hand & Stone is a 550-plus unit massage and facial spa franchise with a mission to bring affordable, luxury spa services to all. Launched in 2004, the company now has locations across 35 states and Canada. Hand & Stone offers its signature hot stone massage, along with other high-quality professional massage services such as Swedish, Himalayan Salt, Sports, Deep Tissue, Oncology and Prenatal. Guests can also visit the spa to enjoy best-in-class facial treatments performed by licensed estheticians. These feature top-of-the-line products backed by science, including Dermalogica and ClarityRx Clinical Skin Care. A wide range of services are available for women, men and teens and are tailored to each individual`s needs or skin concerns. The fastest-growing spa franchise in the country, Hand & Stone has been named No. 1 in the spa category by Entrepreneur Magazine in 2023, 2021 and 2020 and was ranked No. 8 on Forbes` Best Franchises to Buy list in the high investment category.

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.